Istesso
Istesso is a biotechnology company focused on developing treatments that aim for disease resolution rather than modification. Their approach seeks to rebuild damaged tissue, potentially reversing disease and restoring normal function for patients with chronic conditions.
- Leramistat for rheumatoid arthritis
- IST004 for neuroprotection/autoimmunity
- MBS2687 for autoimmune and neuroprotection/fibrosis
Locations
Competitors
Probatech is dedicated to sourcing and connecting innovative pharma companies and investors with unique opportunities in the biotech sector.
William Harvey Research Limited is a contract research organisation established in 1990, specialising in preclinical drug evaluation services for the Biotech and Pharmaceutical sectors.
New Medicine Partners is an advisory company that creates strategies for precision medicine and precision health to advance healthy lifespan.
Company Details
Istesso is operated by Istesso Limited and is a Active company incorporated on 5 May 2017 with the registered office located in London, Greater London. Istesso Limited was registered 8 years ago.
Status
Active
Size
Micro
Directors
8
Age
8 years old
Employees
15
Turnover
£62K
Total Assets
£9.11M
Cash in Bank
£5.03M
Total Liabilities
-£37.88M
Teams
12
10
1
1
Executive Chairman • Joined Apr 2007
Non Executive Director • Joined Sep 2017
Chief Financial Officer • Joined Sep 2021
Chief Medical Officer • Joined Sep 2024
Executive Assistant • Joined Jul 2023
CMC Director • Joined Jan 2024
CMC Project Manager • Joined Jun 2023
Head Of Clinical Operations • Joined Feb 2022
Senior Clinical Project Manager • Joined Feb 2024
Director CMC, Drug Substance • Joined Dec 2023
Executive Chairman • Joined Apr 2007
Non Executive Director • Joined Sep 2017
Chief Financial Officer • Joined Sep 2021
Chief Medical Officer • Joined Sep 2024
CMC Director • Joined Jan 2024
CMC Project Manager • Joined Jun 2023
Head Of Clinical Operations • Joined Feb 2022
Senior Clinical Project Manager • Joined Feb 2024
Clinical Development Consultant • Joined Nov 2023
Clinical Operations • Joined Mar 2023
Executive Assistant • Joined Jul 2023
Director CMC, Drug Substance • Joined Dec 2023
View 12 members